Company Performance Metrics
Thomas Holmes: COO- Helmut Zarbl: Founder and President
GeneAssess, Inc. is a New Jersey-based biotechnology company that is working to validate FRY, a cancer molecular signature gene discovered by GeneAssess scientists that could provide a more accurate diagnostic biomarker for cancer staging.
The FRY gene appears to be found in the breast cancer model but also shows potential for other cancers.
In research performed to date, mutations in the gene increase rat susceptibility to mammary cancer and FRY reduced the growth of highly aggressive human breast cancer cells in animal models.
GeneAssess plans to validate FRY as a predictive biomarker for breast and other cancers, to detect genetic mutations in at-risk populations and to explore target validation for FRY. The company has an exclusive license to the intellectual property developed by Dr. Zarbl.
